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Abstract
Recently available G-protein coupled receptor (GPCR) structures and biophysical studies suggest that the difference
between the effects of various agonists and antagonists cannot be explained by single structures alone, but rather that the
conformational ensembles of the proteins need to be considered. Here we use an elastic network model-guided molecular
dynamics simulation protocol to generate an ensemble of conformers of a prototypical GPCR, b2-adrenergic receptor
(b2AR). The resulting conformers are clustered into groups based on the conformations of the ligand binding site, and
distinct conformers from each group are assessed for their binding to known agonists of b2AR. We show that the select
ligands bind preferentially to different predicted conformers of b2AR, and identify a role of b2AR extracellular region as an
allosteric binding site for larger drugs such as salmeterol. Thus, drugs and ligands can be used as ‘‘computational probes’’ to
systematically identify protein conformers with likely biological significance.
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Introduction
One of the best examples for illustrating the conformational
diversity of biomolecules is the superfamily of G protein-coupled
receptors (GPCR), the largest known superfamily of cell surface
receptors. GPCRs are involved in a number of important ligand-
receptor interactions, including responses to light, odorant
molecules, neurotransmitters, hormones, and a variety of other
signals. Each active GPCR can stimulate hundreds of G-proteins
that represents the first amplification step in the GPCR signaling
cascade [1]. Additionally, cytoplasmic proteins such as kinases and
arrestins also interact with active GPCRs for signal quenching to
prevent persistent receptor stimulation [2]. The fact that ,30% of
all approved drugs target GPCRs highlights their pharmacological
importance [3].
Insights into the conformational states and the complexity of
GPCR dynamics have been obtained from a range of experiments,
which revealed that the activation of GPCRs is a multistep
process, and even at basal activity levels the receptors display
different conformations. Furthermore, different active state
conformations of GPCRs can be stabilized by different agonists,
which results in their association with different downstream
signaling molecules [4–11].
A prototypical GPCR, b2-adrenergic receptor (b2AR), is crucial
for the physiological regulation of cardiovascular and pulmonary
functions through the binding of catecholamines, such as
epinephrine or norepinephrine. b2AR comprises cytoplasmic
(CP), transmembrane (TM), and extracellular (EC) domains
(Fig. 1A, Fig. S1A) and contains a bundle of seven trans-
membrane (TM) helices (H1–H7). The CP domain of b2AR
contains three cytoplasmic loops, CL1–CL3, that connects helices
H1–H2, H3–H4, and H5–H6, respectively. The EC domain
consists of the N-terminus and three interhelical extracellular loops
(EC1–EC3) between TM helices H2–H3, H4–H5 and H6–H7.
EC2 (between H4 and H5) contains a short helix at a position
above the ligand binding cavity at the TM region (Fig. 1A, Fig.
S1A).
Available experimental evidence indicates that GPCRs have
several conserved ‘‘microdomains’’. The allosteric disruptions of
specific contacts and conformational changes at these sites are
crucial for GPCR activation [12]. These microdomains include (i)
the highly conserved (D)ERY motif at the CP end of H3 and the
X1BBX2X3B motif at the CP end of H6 (B, basic; X, non-basic)
[1,13], (ii) the Asn-Asp pair in H1 and H2, and the NPXXY motif
in H7, respectively [14,15], and (iii) the aromatic cluster
surrounding the ligand binding pocket, including the rotamer
toggle [16,17]. Recent publications of several GPCR crystal
structures have in turn prompted several computational studies.
While much attention has been paid to the G-protein binding
motifs at the cytoplasmic region, particularly to the (D)ERY motif
and the salt bridge at the CP sites of H3 and H6 [18–22], the
global dynamics of the entire protein that leads to its activation
and the functional roles of its extracellular sites have only been
explored more recently [23,24].
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We previously developed a multiscale protocol called Aniso-
tropic Network Model (ANM) [25,26] restrained Molecular
Dynamics (MD) [24]. This protocol allows for the sampling of
long time-scale, biologically-relevant global motions of a biomo-
lecular system with realistic deformations in the presence of the
protein’s explicit environment. We previously applied ANM-
restrained-MD to the first structural representative of GPCRs,
rhodopsin, to study its activation mechanism and the interactions
with its ligands [24]. Here, we use the ANM-restrained-MD
protocol to generate conformational ensembles of b2AR. Along
with the existing crystal structures, these conformational ensembles
are probed for binding modes of b2AR by docking its known
agonists against them. Our simulations reveal that, in agreement
with previous experimental data, b2AR alters its ligand binding
site and residues that are critical for ligand binding and activation
to make them accessible for drugs. They also show that agonists
with distinct structures (such as salmeterol and epinephrine [Fig.
S2]) bind to distinct conformations of b2AR. Thus, our simulations
uncover the novel ligand-selected conformers of b2AR that may
engage the distinct sets of interacting proteins for initiating
downstream signaling events, and suggest a generic scheme in
which drugs and innate ligands are used as ‘computational probes’
to identify potential biological conformers of their binding
proteins.
Results
ANM-restrained-MD generated conformations of b2AR
We used an ANM-restrained-MD protocol to generate confor-
mational ensembles of b2AR (Fig. 1B, C). As discussed in the
Materials and Methods section, the lowest 9 modes of ANM were
followed in the plus and minus direction using ANM-restrained-
MD. Figure S3A shows the time evolution of RMSD in Ca
positions from the initial structure along the nine lowest modes
that are used as targets in the MD simulations. The two curves in
each graph refer to the opposite direction deformations. By the
end of each simulation the conformation departs from the original
one by an RMSD of about 1.5 A´˚. Figure S3B shows the time
evolution of RMSD in Ca positions from the initial structure along
the modes that are used as targets in the ANM-restrained-MD
simulations recursively. Ribbon diagrams of select b2AR confor-
mations obtained by these simulations are shown in Figure 1C (see
Text S1 and Figure S3 for additional details).
Figure 1. Protocol for ANM-restrained-MD simulations and b2AR conformations. A. Structure of b2AR. Transmembrane helices 1–7 are
labeled by numbers and colored in red, orange, yellow, green, blue, purple, and pink, respectively. Cytoplasmic helix 8 and the short extracellular
helix below the binding cavity in extracellular loop 2 are colored in cyan. Ligand- and G-protein binding sites are shown by arrows. The palmitolyl
group that is anchored to the membrane from the H8 is also shown in cyan. B. The protocol for generating the ensemble of conformations by ANM-
restrained-MD algorithm. C. Ribbon diagrams of b2AR conformations. Front view (top) and back view (bottom) of b2AR conformers generated by
ANM-restrained-MD are shown.
doi:10.1371/journal.pone.0050186.g001
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Next, we analyzed the motions of b2AR microdomains (Fig. 2,
Fig. S4) in the conformations that have been obtained by ANM-
restrained-MD simulations. In the conformational ensemble, we
find that the hydrogen bond network among H1 and H2 and H7
has the highest rigidity at the cytoplasmic side, mainly due to the
water molecules that exist between the N-D pair and the NPXXY
motif on H7 coordinating the H-bond network. Two residues that
belong to the NPXXY motif at H7, Tyr326 and Asn322 are
connected to Asn51 on H1 and Asp79 at H2 through four water
molecules located in the cavity between H1, H2 and H7 (Fig. 2A).
Previous experimental evidence demonstrated that at least two
of the three serine residues at H5 (Ser203, Ser204 and Ser207) are
important for the binding of agonists with the catechol moiety.
Only Ser203 is accessible to the binding pocket in the carazolol-
bound inactive form of b2AR [27]. Our simulations show that the
transposition of H5 with 1.5 A˚
´
toward the ligand binding pocket is
sufficient for the accessibility of all three serine residues in the
binding pocket. The simulations also reveal that in the absence of
ligand a water molecule migrates and interacts with Ser203 and
Ser207 (Fig. 2C).
At the EC site of b2AR, EC2 and H7 are connected with a salt
bridge between Asp192-Lys305 [4]. During ANM-guided-MD
simulations, the distance between Asp192 and Lys305 ranges from
1.8 A˚
´
to 4.3 A˚
´
. Figure 2C shows the extracellular site of the
carazolol-bound inactive crystal structure superimposed on the
ANM-restrained-MD conformation obtained by steering along the
eighth mode of ANM in MD simulations. The residues Asp192 at
EC2 and Lys305 at H7 are displayed in both structures (Fig. 2C).
In the carazolol-bound inactive b2AR structure Asp192-Lys305
forms a salt bridge with a distance of 1.8 A´˚. In the conformation
generated by the ANM-restrained MD this salt bridge is broken
and the distance is increased to 3.5 A´˚. Furthermore, the entire
EC2, including the short helix that occupies a position below the
ligand binding site moves away from EC3 as well as from the
ligand binding pocket. This indicates that the EC site is flexible for
ligand diffusion and accommodates the ligands by coupling to the
ligand binding site.
Conformations of binding site residues
As it is detailed in the Methods section (see also Fig. S5), we used
the XCluster module of the Schrodinger suite [28] for choosing
the representative conformations that the agonists were docked
against. The root mean square deviation (RMSD) of the residues
that have been shown previously to be critical for the ligand
binding and activation of the protein were used as the clustering
criteria. The conformations of the residues are displayed on the
structures that are selected by the XCluster, shown in Figure S6.
ANM-restrained MD conformations that accommodate
salmeterol and epinephrine
After choosing the representative conformations by Xcluster, we
docked the agonists against them using the Glide SP and XP as
incorporated in the Schrodinger Suite [29,30]. The resulting
complexes were selected based on both their GlideXP scores and
their poses, i.e. the geometries of the agonist-protein interactions
that had been shown to be critical for ligand binding and protein
activation (see Table 1 for b2AR agonist binding residues and the
agonist motives that are known to bind them) [10,16,17,31–39].
This allows the selection of ANM-restrained-MD generated b2AR
conformations that bind most favorable to known agonists. For
example, the most favorable b2AR-salmeterol complex derives
from the conformation that was obtained by steering the ANM-
restrained-MD along the eighth mode in the minus direction (8M).
Similarly, the most favorable b2AR-epinephrine complex is
derived from the conformation that is found by following the
second mode in plus direction (2P) in the ANM-restrained MD
simulations. The b2AR-formoterol complex has been obtained by
an ANM-restrained-MD conformation that is obtained by a
combination of modes (first mode in plus, second mode in minus
and third mode in minus directions) by using the algorithm
described in the methods section (Figs. S3B and S10). It should be
noted that the starting structures of the ANM-restrained-MD
simulations do not give good scores or poses for any of the three
known agonists, which is to be expected considering the fact that
they are derived from the crystal structure of the inactive form of
b2AR. To show the similarity of the modes (the ANM-restrained-
MD targets) to the resulting ANM-restrained MD conformations
we have calculated the RMSD per residue between them. Figure
S7 shows the RMSD per residue graphs and ribbon diagrams for
8M and 2P and their target ANM modes. The left panel shows
RMSD profiles of Ca as a function of residue index, reached by
the ANM-restrained MD protocol using modes 8 in minus (8M)
and 2 in plus (2P) directions. The right panels show ribbon
diagrams of 8M (A) and 2P (B) b2AR conformations. As it can be
observed from Figure S7 both of the ANM-restrained MD
Figure 2. Microdomains of b2AR stabilized by new interactions
and water molecules. A. Water molecules stabilizing the conserved
NPXXY motif (left) and the Asn-Asp pair (right) within the transmem-
brane region, and (B) the critical catecholamine binding Ser203 and
Ser207 residues at H5 in conformations where they both point to the
ligand binding pocket and connected through a water molecule. C. The
motion of extracellular loop two (EC2) and the residues that form the
salt bridge at the EC site. The motion found by ANM-restrained-MD to
break the salt bridge at the extracellular site and the opening of the
extracellular site is shown. ANM-restrained-MD conformation and the
carazolol-bound structures are in solid and transparent colors,
respectively. The side chains of Asp192 at EC2 and Lys305 at H7 that
form the salt bridge at the inactive state of b2AR are displayed on both
structures. The motion of the EC2 including the short helix is depicted
by red arrows.
doi:10.1371/journal.pone.0050186.g002
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conformations that form complexes with epineprine and salme-
terol reach their corresponding target ANM modes.
To compare the sizes and the locations of epinephrine,
salmeterol and BI-167107 (the insoluble agonist crystallized in
the active structures of b2AR) [22,40] in the protein-ligand
complexes, we examined the molecular surfaces of these ligands
using MOE (Molecular Operating Environment, Chemical
Computing Group Inc.). Ribbon diagrams of b2AR conformations
are shown in gray in Figure S8. The head groups of all agonist are
located at the orthosteric binding pocket and they interact with the
Serine residues at H5 that are rotated towards the binding pocket
in the ANM-restrained-MD conformations. While epinephrine
populates only the orthosteric binding site both BI-167107 and
salmeterol protrudes to the extracellular region.
To further analyze the complexes we generated RMSD per
residue graphs between the starting structures and the ANM-
restrained-MD conformations (Fig. 3). In both complexes, not only
the cytoplasmic region that bind to G-protein (CL2, CL3 and the
cytoplasmic ends of the connecting helices) but also the
extracellular region (including the loops EC1, EC2 and EC3)
exhibit higher mobility. Although the overall RMSD profile of the
extracellular region tends to maintain similar features in both
conformations, 8M has larger structural rearrangements at EC2
and at the extracellular end of the helices that are connected by
this loop. These structural arrangements lead to the accommoda-
tion of salmeterol at the extracellular region.
Binding of the long-acting agonist, salmeterol
Similar to a typical b2AR agonist, salmeterol contains a
secondary amine, a chiral b-hydroxyl group, and an aromatic
ring that enables it to bind to the orthosteric binding pocket.
Figure 4 displays the interactions of salmeterol bound to a b2AR
conformation from the ANM-restrained-MD. The hydroxyl
groups of its aromatic ring form hydrogen bonds with Ser203
and Ser207 at H5 that are rotated toward the binding site at this
conformation. These interactions are consistent with the results of
mutagenesis- and molecular modeling studies showing that
Ser203, Ser204, and Ser207 are the contact residues for the
catechol hydroxyl groups of the agonists [33,34,37]. The
protonated amine interacts with Asp113 at H3 and the b-hydroxyl
group interacts with both Asp113 at H3 and Asn293 at H6. These
interactions of the ligand serve as a bridge at the ligand binding
site for connecting H3 and H6 that play a critical role for allosteric
signal propagation from the ligand binding site to the cytoplasmic
end of these helices to interact with the G-protein.
Previous experiments also verified that the interactions of the
protonated amine and the chiral b-hydroxyl of the agonists with
Asp113 at H3 and Asn293 at H6 are necessary for b2AR
activation [35,36,38]. It has also been shown that the catechol-
amine aromatic ring interacts with a cluster of aromatic residues
(including the so-called ‘rotamer toggle switch’) that are highly
conserved among the Class A GPCR family that may modulate
the movement of H6, and thus may be critical for the activation of
this class of GPCRs [16,17]. Within the conformations of the
b2AR-salmeterol complex the aromatic ring of salmeterol p-stacks
with Phe290 at H6 (Fig. 4D) and with Val114 at H3, indicating
that the aromatic ring is restrained between Val114 at H3 and
Phe290 at H6. This finding is in agreement with the site directed
mutagenesis experiments that show the size and orientation of
Val114 to be critically important for the binding of aromatic rings
of agonists [31]. The same interactions were observed when
salmeterol was docked to the recently published active structure of
b2AR bound to the agonist, BI-167107 [22,41] (Fig. 5).
The docking results also show that salmeterol has a long
lipophilic tail that extends to the orthosteric pocket formed by
helices 3–7 (Fig. S2B). The tail region of salmeterol runs parallel to
the EC2 (Fig. 4B). It has been suggested previously that salmeterol
binds not only to the orthosteric pocket formed by the H3–H7
pocket of b2AR but also at a second site or ‘exosite’, possibly
formed by a hydrophobic region of H4, or a localized membrane
region in the vicinity of the receptor [42]. Docking salmeterol
against the ANM-restrained-MD conformations and the crystal
structure showed that the tail region of salmeterol can be
accommodated at the EC region of b2AR by hydrophobic
interactions with the extracellular site (Figs. 4, 5). The oxygen
atom at the bending region of salmeterol forms a hydrogen bond
interaction with Tyr308 at H7, and its aromatic ring is at the
vicinity of Phe193 at EC2 (Fig. 4C). The BI-167107 bound crystal
structure in the active conformation has two additional residues
(Ile309 at H7 and Phe194 at EC2). These residues are labeled in
red in Figure 5.
Binding modes of the natural ligand, epinephrine
Next, we used the ANM-restrained-MD generated conforma-
tions and the BI-167107 bound crystal structure to explore the
binding modes of the endogenous ligand, epinephrine, to b2AR.
Figure 6A shows the geometry of a complex obtained by docking
epinephrine to a conformation derived from the ANM-restrained
MD. In this complex, both the meta- and para-hydroxyl groups of
the catechol ring of epinephrine (Fig. S2A) are interacting with
Ser203 and Ser204, respectively. Furthermore, both the b
hydroxyl- and the amine groups of epinephrine are forming
hydrogen bonds with Asp113 in this complex. Site directed
mutagenesis experiments show that interactions of both hydroxyl
groups of the catechol ring with serine residues at H5 is necessary
for the full efficacy of epinephrine, and that the binding affinity is
abolished when either the catechol hydroxyls or the hydroxyl
group on the side chain at positions of Ser203, Ser204, or Ser207
Table 1. b2AR residues that are shown to be interacting with agonists.
Helix Residue Agonist motifs Reference
H3 Asp113, Val114 b-OH Strader et al., 1988; Chung et al., 1988; Wieland et al., 1996; Balmforth et al., 1997;
Swaminath et al., 2005; Arakawa et al., 2009
H5 Ser203, Ser204, Ser207, Pro211 Head group OHs Strader et al., 1989; Liapakis et al., 2000, Swaminath et al., 2005
H6 Phe282, Trp286, Phe289, Asn293,
Asn297
Head group (Phe 282, Trp286,
Phe289), Protonated amine
(Asn293)
Strader et al., 1994; Cho et al., 1995; Javitch et al., 1998; Shi et al., 2002; Chen et al.,
2002; Swaminath et al., 2005
H7 Tyr308, Asn312, Try316 Ethanolamine tail Huber et al., 2008; Ahuja & Smith, 2009
doi:10.1371/journal.pone.0050186.t001
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are removed [36,37]. The amines of agonists, partial agonists, and
antagonists all share an interaction with Asp113 [35]. Therefore,
structural differences in the aromatic components of ligands are
the primary determinants of efficacy.
Next, we analyzed the interaction of epinephrine with the BI-
167107 bound active b2AR crystal structure (Figs. 6B, S9). The
highest ranking pose of epinephrine is located at the orthosteric
binding pocket near the experimentally verified ligand binding
residues, but does not form hydrogen bonds with any of these
residues such as serines at H5 and Asn113 at H3 (Fig. 6B). In the
pose with the second highest score, epinephrine is located at the
lower binding site that is suggested for binding of salbutamol closer
to the EC loops [10]. At this pose, one of the hydroxyl groups of
the catechol is forming a hydrogen bond interaction with Ser203,
while the other hydroxyl group is closer to Tyr308 at H7 but not
forming any hydrogen bond interaction. Figure S9B shows this
pose from a top view from the cytoplasmic site of b2AR. The
catechol ring of epinephrine is located between Phe193 at the EC
loop 2 and Phe289 at H6, forming p-stacking interactions with
both of these residues. Asp113 at H3 and Asn312 at H6 are at the
closer vicinity of the b-hydroxyl and amine groups of epinephrine.
Therefore, the innate ligand of b2AR (i.e., epinephrine) requires
an alternative active b2AR conformer for optimal binding and
does not bind the published active crystal structure of b2AR.
Discussion
Understanding the conformational dynamics of b2AR and other
GPCRs is essential to gain insights to the mechanism of action of
their natural- and synthetic ligands. The studies presented here
provide new insight into the dynamic behavior of GPCRs that are
not addressable by static crystal structures and cover a larger part
of the conformational space of the protein through the use of the
ANM guided MD simulations. The extracellular site is important
for ligand diffusion and stabilization and plays a critical role in the
activation of b2AR and the duration of its active states as well as
other GPCRs [1]. The motion of EC2 helix and the breakage of
the salt bridge between EC2 and H7 that are predicted here might
be important for both ligand diffusion and structural arrangements
of the EC site in order to accommodate the ligands by coupling
them to the ligand binding site. Conformational flexibility of the
EC site has been also demonstrated by amide hydrogen/
deuterium exchange studies [23]. Additionally, NMR data also
suggested that the Asp192-Lys305 salt bridge is weakened in the
b2AR active state and agonists induce ECs conformational
changes that differ from those induced by inverse agonists [4].
Furthermore, these studies also give insights about conformational
coupling between the EC site and the orthosteric binding site
showing that drugs targeting these sites as allosteric modulators
with high subtype selectivity.
In the present work we observed that salmeterol occupies the
orthosteric binding site by forming the necessary interactions that
are critical for full agonist activation (Figs. 4 and 5). The long tail
of salmeterol bends and runs almost parallel to EC2 (Figs. 4 and 5).
Among the notable structural differences between b2AR and
rhodopsin are their extracellular regions: the EC2 loop of
rhodopsin forms a b-strand that serves as a lid to both inverse
agonist and full agonist forms of retinal, running almost parallel to
its polyene chain [12,43,44]. Analysis of metarhodopsin II (the
active state of rhodopsin) decay and folding experiments show that
mutations localized near the ligand-binding pocket and EC2 are
important both for the stability of both active and inactive
conformations as well as for the correct folding of the protein
[12,12,24,45–47]. Furthermore, NMR data for both rhodopsin
and b2AR showed that ligands known to differentially affect the
cytoplasmic site conformation also stabilize distinct EC confor-
mations [4]. High affinity and prolonged agonist effect of
salmeterol could be explained by its additional interactions with
the extracellular region of b2AR and forming a similar ‘lid’ for the
rest of the drug that shares high structural homology with other
agonists.
Salmeterol is structurally very similar to the partial agonist
salbutamol except for its long and flexible tail (see Fig. S2). For the
bronchodilator peak effects, 50 mg of salmeterol is equipotent to
200 mg of salbutamol and its effect lasts approximately 4 times
Figure 3. RMSD profiles as a function of residue index for the ANM-restrained-MD conformations that accommodate salmeterol
and epinephrine. Red and blue curves represent RMSD per residue between the starting structure and the conformations that accommodate
salmeterol and epinephrine, respectively. In both complexes, not only cytoplasmic region that binds to G-protein but also the extracellular region
exhibits higher motilities. Although the overall RMSD profile of the extracellular region tends to maintain similar features in both conformations, 8M
has larger structural rearrangements at EC2 and at the extracellular end of the helices that are connected by this loop. These structural arrangements
lead to the accommodation of salmeterol at the extracellular region. The sequence ranges of the helices (H1–H8) are indicated by the labels on the
upper abscissa and distinguished by gray bands. The color code of the helices that are used in the ribbon diagrams of b2AR are also displayed as
colored bands at the bottom of the graph.
doi:10.1371/journal.pone.0050186.g003
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longer than that of salbutamol. Both of these drugs have a
hydroxymethyl substituent in the meta position of the aromatic
ring instead of a hydroxyl group (Fig. S2) and this is the only
difference between a full agonist catecholamine, such as epineph-
rine and salbutamol. It has been suggested that this minor
difference would lead salbutamol to bind to a site at the EC region
Figure 4. Binding of salmeterol to b2AR. A. Interactions of salmeterol at the binding site of an ANM-restrained-MD conformation; B. The location
of salmeterol tail forming a ‘lid’ with the extracellular loop 2 (EC2) of b2AR from the extracellular site view. The flexible tail of salmeterol folds parallel
to the EC2 and stabilizes the rest of the ligand forming a lid at the extracellular site. The green arrow shows the direction that the salmeterol tail runs
similar to a beta-sheet structure. C. The residues lining the salmeterol binding pocket; D. The stabilization of the aromatic ring of salmeterol by
Val114, Thr118 at H3, Ser203 and Ser207 at H5, and Phe290 atH6. Carbon, oxygen, nitrogen and hydrogen atoms of salmeterol is colored green, red,
blue and white; respectively. ANM-restrained-MD conformation that is able to accommodate inside the ligand binding pocket is shown in ribbon
diagram with transparent helices. The residues with the majority of atoms within the 3.5 A˚
´
making specific interactions with salmeterol are displayed.
The EC2 that closely interacts with salmeterol is also show in green ribbon diagram.
doi:10.1371/journal.pone.0050186.g004
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instead of the orthosteric site that catecholamines bind [10].
However, salmeterol forms the necessary interactions at the
orthosteric binding pocket and the lipophilic tail region is located
at the lower binding site suggested for salbutamol binding. It is
possible that the stabilization of extracellular site by the tail of
salmeterol would lead the rest of the molecule to diffuse to the
orthosteric site and form the critical interaction for receptor
activation synergistically, as has been suggested previously for
other ligands [34].
We have observed that the endogenous ligand epinephrine is
located at the orthosteric binding pocket forming the experimen-
tally verified interactions in an ANM-restrained MD-epinephrine
complex (Fig. 6). However, these interactions are not able to form
the full agonist interactions at the orthosteric binding site of active
BI-167107 bound form of b2AR (Fig. S9). The antagonists and
inverse agonists of b2AR have bulky aromatic groups (see the
structure of carazolol in Fig. S2) and these groups are located
between the H4, H5 and H6 where agonists with smaller aromatic
rings containing hydroxyl groups similar to catechol moiety of
epinephrine that binds to b2AR. The recently determined active
structure of b2AR has been crystallized with BI-167107. This
ligand’s bulky aromatic group contains the features of both
agonists and antagonists and it interacts with the residues that
comprise the binding pocket of both agonist and antagonists (Figs.
S2 and S8) [48]. Hence the binding pocket of BI-167107 is quite
large. This might be the underlying the reason for a larger agonist,
such as salmeterol, forms the experimentally verified interactions
with active BI-167107 bound form of b2AR crystal structure while
epinephrine is stabilized with two aromatic residues that are close
the extracellular region and it is not stabilized by the experimen-
tally verified interactions in the orthosteric binding pocket in this
structure.
While this and previous studies have shown that the members of
one conserved microdomain that compromise the NPXXY motif
at H7 and the Asp-Asn pair at H1 and H2, are connected through
water molecules [19,24,49], the existence of these water molecules
in the active states of b2AR that couple to its downstream
molecules such as G-proteins still remains to be explored. The
Figure 5. Binding of salmeterol to the active BI-167107 bound
form of b2AR. Salmeterol occupies the same location in the crystal
structure of the active b2AR as we identified by ANM-restrained-MD for
the conformation-salmeterol complex. The residues that have atoms in
3.5 A˚
´
are displayed and those that are not interacting with salmeterol in
ANM-restrained-MD conformation are labeled in red. These are Trp286
at H6, Ile 309 at H7, and Phe194 at EC2. Carbon atoms of salmeterol are
colored in pink. The rest of the atoms are colored the same as in
Figure 3.
Figure 6. The complexes of epinephrine with an ANM-restrained-MD conformation and the active crystal structure. A. ANM-
restrained-MD conformation-Epinephrine Complex. Epinephrine is located at the orthosteric binding site. The meta- and para- hydroxyl groups of the
catechol ring are interacting with Ser203 and Ser204 at H5, respectively. Both b-hydroxyl and amine groups of epinephrine are forming hydrogen
bonds with Asp113. The carbon atoms of epinephrine are colored green. B. BI-167107 bound active structure-Epinephrine Complex. The first pose of
epinephrine in the BI-167107 bound active structure is located at the orthosteric binding pocket near the experimentally verified ligand binding
residues active crystal structure. However, it is not forming any hydrogen bonds with any of these residues such as serines at H5 and Asn113 at H3.
doi:10.1371/journal.pone.0050186.g006
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resolutions of the BI-167107 bound active states b2AR structures
do not permit the identification of the water molecules within the
protein. The binding of G-proteins leads to further conformational
changes in GPCRs to stabilize their active state [8,22,50]. During
these arrangements water molecules may be replaced by proteins
coupled to GPCRs. Experimental studies have shown that the
NPXXY motif at H7 and the Asp-Asn pair at H1 and H2,
respectively, have additional roles in mediating interactions of
GPCRs with their downstream proteins of the signaling pathway
other than G-protein coupling, such as G-protein activation
[32,34,35,51], binding preferences to different G-proteins [14],
and agonist-mediated receptor sequestration [52]. For example,
the Asn391Ala mutation at the NPXXY motif of the Cholecys-
tokinin B receptor abolishes Gq protein activation without
affecting its association with the receptor [51]. Another site
directed mutagenesis study showed that Asn376Glu mutation in
the NPXXY motif within the 5-HT2A receptor changes its
binding preference from small G protein to an alternative isoform
[14]. It has also been shown that the mutation of Tyr326Ala
completely abolishes agonist-mediated receptor sequestration of
b2AR for undergoing rapid desensitization, and down regulating
in response to agonist [52]. These findings are also verified by
19FMR spectroscopy showing that the NPPXY motif may be
important for arrestin binding [53]. The effects of mutations on
the N-D pair have also been investigated. The Glu79Asn mutation
decreased the potency and maximal activity of epinephrine to
stimulate cAMP accumulation generating a ‘‘constitutively inac-
tive’’ mutant [35].
From a more general perspective, the interactions that a drug
target has with its ligands represent a subnetwork within a network
of interactions of all drugs [54,55]. Yet, the particular protein
conformations that a drug preferentially binds are ignored in these
representations. However, it is a well-known fact that different
states of proteins participate differentially in protein-protein
interaction networks. Furthermore, binding of structurally differ-
ent agonists might entail the disruption of different combinations
of these intramolecular interactions, leading to different receptor
conformations and differential effects on downstream signaling
proteins. This information is valuable for designing functionally
selective protein modulators. GPCR signaling networks are one of
the best examples that illustrate the effects of conformational
complexity of biomolecules in protein-protein interactions. Func-
tional and biophysical studies show the existence of multiple,
ligand-specific conformational states of GPCRs. They suggest that
agonist binding and activation occur through a series of
conformational intermediates linking an inactive receptor to a
fully active one. These intermediate conformational states
generated during agonist binding and activation may have unique
functional properties and implications for cellular signaling [9,56].
Here, we identified different conformations that form complexes
with structurally different agonists (Fig. S10). Furthermore, b2AR
is known to activate both Gs and Gi, as well as non-G protein-
dependent signaling pathways [5,57,58]. Thus, different agonists
initiate specific series of signaling and regulatory events by
inducing and stabilizing different sequence of conformational
states. To develop a more refined understanding and abstraction
of ligand- and drug-target interactions the computational
approach that we have developed here as a proof of principle
can be used to systematically identify functionally relevant protein
conformation-drug complexes. Thus, rather than considering a
protein as one single molecular species these functionally relevant
conformations could be represented and viewed as individual
nodes in greatly expanded protein-protein and protein-drug/
ligand interaction networks (Fig. S13).
Materials and Methods
In addition to the carazolol bound inactive crystal structure
(2RH1.pdb, 2.4 A˚
´
), the initial structures of the ANM-restrained-
MD simulations were derived from a previous MD study of b2AR
[19] and kindly provided us by the Shaw group. In their study, the
crystal structure of b2AR in its inactive conformation subjected to
millisecond MD simulations using Desmond [59]. These simula-
tions converged to two different conformations, an ‘‘open’’ form of
the ERY motif, containing no salt bridge between Arg131 at H3
and Glu268 H6 and a ‘‘closed’’ form of the ERY motif. Two
representative conformations was used as starting structures for
ANM-restrained-MD protocol with the open form of ERY motif,
one snapshot at 729 ns from the simulation of the apo form of
b2AR, and the other at 515 ns from the simulations of the partial
agonist, carazolol-bound form of b2AR. The superimpositions of
these snapshots to the crystal structure of the inactive form of
b2AR (2RH1.pdb, 2.4 A˚
´
resolution) have shown in Figure S11 and
further analysis of them is provided in Text S1 page S17. The
crystal structure of the inactive form of b2AR was also inserted into
the lipids obtained from these long MD simulations. This strategy
was chosen to improve on the resolution of the crystal structures
and to obtain initial structures that are closer to the conformation
in the membrane rather than the crystal environment.
Each system consists of b2AR embedded to a large, equilibrated
palmitoyl-oleolyl-phosphatidyl-ethanolamine (POPE) bilayer with
170 lipid molecules, 18 sodium ions, 23 chloride ions, and 8,500
water molecules, for a total of ,51,000 atoms, and measured
85675685 A˚´ (Fig. S1A). In these systems, all Lys and Arg residues
were protonated and all His, Glu, and Asp residues were
deprotonated, except Glu122, which makes contacts with the
lipid tails and thus likely exists in the protonated state. The system
also includes the S-palmitoylation at Cys341 (shown in dark blue
in Fig. S1). The procedures outlined in the Nanoscale Molecular
Dynamics (NAMD) [60] tutorial on developing topology and
parameter files were used to generate force field parameters for the
thioester linkage between Cys341 and the palmitoyl group. There
are two disulfide bridges between Cys106 and Cys191 and
between Cys184 and Cys190 close to the EC site (shown in dark
blue in Fig. 1C). We followed the membrane tutorial of NAMD to
prepare the topology, parameter and psf files that associate these
systems to run MD simulations in NAMD. To generate the
ensemble of conformations using ANM-restrained-MD, we
developed a fully automated code that works in NAMD and that
is available from the first author (B.I.) upon request.
The Generation of b2AR conformers using ANM-
restrained-MD
In ANM-restrained-MD, an ensemble of ANM modes is used in
an iterative scheme, as described in Figure 1B. Essentially, the
algorithm generates a succession of conformations using ANM
modes as harmonic restraints in MD runs, succeeded in each case
by a short energy minimization algorithm to allow the molecule to
settle in a local energy minimum. To this end, we first selected a
pool of low frequency ANM modes. In the case of b2AR, the
lowest frequency modes were observed to be the most cooperative
ones, and the frequency distribution indicated that the subset of
the first nine modes were separable. Therefore, the first nine
lowest frequency modes were selected by using eigenvalue
dispersion and the cooperativity criteria (see Text S1 for further
details). Then, for each mode we defined two target conformations
and performed short MD simulations (2500 ps) in the presence of
harmonic restraints that favor these target structures. Since the
restraints may lead to unrealistic strains in the structure, we also
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performed a short energy minimization (1,000 steps) succeeding
each run and the resulting conformations were collected and used
as the input conformations of the next round of ANM-restrained-
MD. They are also used as the starting structures for the
application of the next mode as new harmonic restraints. After
screening all selected modes, this procedure ends. The underlying
assumption in this protocol is that ANM-derived restraints drive
the excursion of the molecule toward a direction that would
otherwise be naturally selected at much longer times. A detailed
description of the protocol is provided in Text S1.
The clustering of ANM-restrained-MD generated b2AR
conformers
For clustering of ANM-restrained-MD conformations the
hierarchical clustering algorithm implemented in the XCluster
[28] module of the Schroedinger 2010 Suite was utilized. First,
Xcluster calculates the pairwise inter-conformational distance
matrix. To define a hierarchy of clusters, it then uses an
agglomerative, ‘‘single link’’ clustering method. It utilizes the
separation ratios to determine the quality of the clusterings. The
separation ratio is defined as the ratio of the shortest inter-cluster
distance to the characteristic threshold distance defining the
clustering. High values of the separation ratio distinguish the good
clusterings. Figure S5 shows the minimum separation ratio of the
clusters obtained versus the clustering level. The representative
conformations that are chosen by XCluster in the clusters with the
highest minimum separation ratio and the clustering level (labeled
with a red circle in Fig. S5). These ligand binding residues that are
listed in Figure S6D is used as the RMSD criteria of the XCluster.
Clustering by the XCluster was performed using the RMSD
displacements of b2AR residues that have been shown experi-
mentally to be critical for the binding of drugs to b2AR: Trp109,
Asp113, Val114 at H3; Ser203, Ser204, Ser207, and Pro211 at
H5; Phe282, Trp286, Phe289, Phe290, Asn293, Ile294, and
Asn297 at H6; Tyr308, Asn312, and Tyr316 at H7
[10,16,17,27,31–39,61,62]. Selection of representative conforma-
tions from each cluster gave 11, 9 and 20 conformations from the
ensembles using the 729 ns Apo form, the 518 ns carazolol-bound
form, and the inactive b2AR crystal structure, respectively. The
conformations of the residues in the cluster are shown in Figure
S6.
The docking a set of known agonists of b2AR against the
selected conformers
We first selected structurally a set of b2AR agonists (e.g.,
salmeterol, epinephrine and formoterol) with known binding
affinity values for docking. In the case where three dimensional
structures were available for these ligands we downloaded them
from the Drugbank (http://www.drugbank.ca/). Otherwise, we
built their structures using the Maestro tools of the Schrodinger
suite.
Before the docking calculations we used the protein preparation
wizard and grid generation tools of Schrodinger 2010 to prepare
the selected b2ARconformers for docking. The docking studies
were conducted with the Glide standard precision (SP) and extra
precision XP [29,30] module from Schro¨dinger for all 40 of the
b2ARconformers.
We selected the conformations that bind the agonists using two
criteria: 1. GlideXP scoring function (G-score). 2. Position and
location of the agonists within the protein and their interactions
with residues that are shown to be critical for the receptor binding
and activation by experimental studies.
First the conformations that bind the ligands with the highest
affinity have been selected by using G-score. This scoring function
has been previously tested with a diverse set of ligands and
receptors and it is built into the Schrodinger Suite. Briefly, G-score
consist of the terms as the major potential interactions contributors
to protein-ligand binding affinity such as the displacement of
waters by the ligand from hydrophobic regions of the protein
active site, protein–ligand hydrogen-bonding as well as other
strong electrostatic interactions, desolvation effects, entropic effects
due to the restriction on binding of the motion of flexible protein
or ligand groups. The pose viewer tool of the Glide XP displays
the different conformations/poses of ligands within the complexes
in the order of their corresponding G-scores. Each ANM-
restrained-MD conformation and an agonist complex generated
by Glide XP has been analyzed using the pose viewer tool and the
agonist pose with the highest G-scores have been chosen for each
protein conformation.
Second, we collected the ligand and protein interactions that are
crucial for the ligand binding and the protein activation from the
literature. For example, it has been shown that the agonists with
the catecholamine moiety interact with at least two of the three
Serine residues (Ser203, Ser204 and Ser207) at H5. It is also well
demonstrated that the interaction of Asp113 at H3 with certain
ligands with their hydroxyl and amines groups) are crucial for
stabilizing them in the binding pocket. The amino acids that are
involved in the ligand binding and activation have been identified
by site-directed mutagenesis, fluorescence spectroscopy, constitu-
tively active and inactive mutants of b2AR as well as the different
derivative of the agonists. Table 1 lists these residues and the
agonist motives that bind to them along with the studies that
identified the interactions [10,16,17,27,31–39,61,62].
The docking of a compound derived from a different
crystal structure
The aim of the protocol that was described above was to find
conformations that accommodate agonists with different structures
and sizes by starting with an inactive structure that cannot
reproduce the interactions that are known to be critical for the
agonist binding and protein activation. Additionally, we tested this
protocol by using a compound as a probe of conformations
derived from a different crystal structure. To this end, we retrieved
an inactive crystal structure of alprenolol-b2AR complex
(3NYA.pdb and 3.16 A´˚ resolution) from the Protein Data Bank.
Subsequently, we docked alprenolol to the ANM-restrained-MD
generated conformations. Then we screened the conformation-
ligand complexes having the highest binding G-scores for the
interactions that have formed in the crystal structure. The complex
that reproduced these interactions and has the closest side chain
and the ligand conformations is displayed in Figure S12A and
Figure S12B displays the interactions of alprenolol in the crystal
structure.
Supporting Information
Text S1 This supporting information provide further details for:
A. Generating protein conformers with ANM-restrained MD B.
Comparison of the snapshots from the millisecond scale MD
simulations of tthe inactive b2AR that are obtained from the Shaw
group with the crystal structure of the inactive b2AR with
carazolol C. Binding of Alperenolol to ANM-restrained-MD
conformations.
(PDF)
Figure S1 The b2AR system and the schematic view for
generating the tree of the conformation ensemble by
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ANM-restrained MD protocol A. b2AR embedded into a lipid
bilayer and hydrated by water molecules. The group that attaches
Cys341 to the membrane as well as the two disulfide bridges
between Cys106 and Cys191 and between Cys184 and Cys190 are
colored in blue. B. The schematic view for generating the tree of
the conformation ensemble by ANM-restrained-MD protocol
using three modes. For illustration purposes the ribbon diagrams
of the starting- and two conformations (in opposite directions, plus
and minus,) derived from the first mode of adenylate kinase are
shown.
(TIF)
Figure S2 The ligands of b2AR that are used in this
study.
(TIF)
Figure S3 Root mean square per time profile of ANM-
restrained MD simulations of b2AR. Figure 3A and 3B
illustrate the representative time evolution of the RMSD in Ca
positions from the initial structures. Figure 3A displays the
RMSDs for the ten slowest modes that are used as targets in the
ANM-restrained-MD simulations. The two curves in each graph
refer to the opposite direction deformations. By the end of each
simulation the conformation departs from the original one by an
RMSD of about 1.5 A˚
´
. The modes that are used as targets are
labeled for each graph are labeled. Blue and red curves represent
the simulations in plus and minus directions, respectively.
Figure 3B shows a representative time evolution of RMSD in Ca
positions from the initial structure in the ANM-restrained-MD
simulations iteratively, as described in the Methods section.
(TIF)
Figure S4 Ribbon diagrams of b2AR ANM-restrained-
MD conformations. Front view (A-left column) and back view
(B-left column) of b2AR conformers generated by the ANM-
restrained-MD are shown. Cell membrane-spanning helices and
extracellular and cytoplasmic regions are shown in different colors
and denoted by numbers. Water molecules stabilizing the
conserved NPXXY motif (A-right column) and the Asn-Asp pair
within the transmembrane region and the critical catecholamine
binding Ser203 and Ser207 residues at H5 (B-right column) in
conformations where they both point to the ligand binding pocket
are shown.
(TIF)
Figure S5 Clustering ANM-restrained-MD b2AR confor-
mations. Clustering results of b2AR conformations by the
XCluster module of Schrodinger. The residues that are shown
to play a critical role in the binding of ligands to b2AR were used
as root mean square fluctuations criteria of XCluster. The clusters
with the highest minimum separation ratio and the clustering level
have been selected.
(TIF)
Figure S6 XCluster-selected conformations of b2AR. The
side chains of the binding site residues that are used in the
clustering criteria in XCluster are shown at H3 and H4 (A), H5
and H6 (B) and the extracellular region (C). The ligand binding
residues that are used in XCluster as RMSD criteria are listed (D).
(TIF)
Figure S7 The comparison of the target ANM modes
and their corresponding ANM-restrained-MD confor-
mations. The left panels show the RMSD per residue profiles
between the ANM modes and their corresponding ANM-
restrained MD conformations for mode 8 in minus direction
(8M) that forms the complex with salmeterol (A) and for mode 2 in
plus direction (2P) that forms the complex with epinephrine. The
right panels show ribbon diagrams of 8M (A) and 2P (B) b2AR
conformations. The CA carbons of ANM modes and their
corresponding ANM-restrained MD conformations are diplayed
as red and blue spheres respectively. The helices are colored in
accord with the rest of the manuscript. The color code of the
helices that are used in the ribbon diagrams of b2AR are also
displayed as colored bands at the bottom of the graphs.
(TIF)
Figure S8 The size and the location of b2AR agonists in
the protein-ligand complexes. The head groups of all agonist
are located at the orthosteric binding pocket and they interact with
the Serine residues at H5 rotated towards the binding pocket.
While epinephrine populates only the orthosteric binding site both
BI-167107 and salmeterol protrude to the extracellular region.
The head groups of all agonist are located at the orthosteric
binding pocket interacting with the Serine residues at H5 rotated
towards the binding pocket. Ribbon diagrams of b2AR confor-
mations are shown in gray. Molecular surfaces of the ligands are
created by using MOE. Green, purple and blue regions of the
ligands are hydrophobic, hydrophilic and mildly polar, respec-
tively.
(TIF)
Figure S9 Binding of epinephrine to the active BI-
167107 bound form of b2AR. A. The first pose of epinephrine
in the BI-167107 bound active structure is located at the
orthosteric binding pocket near the experimentally verified ligand
binding residues active crystal structure. However, it is not forming
any hydrogen bonds with any of these residues such as serines at
H5 and Asn113 at H3. B. In the second highest rank pose of
epinephrine in the active BI-167107 bound structure it is located
at the lower binding site closer to the EC site. At this pose, one of
the hydroxyl groups of the catechol is forming a hydrogen bond
interaction with Ser203 while the other hydroxyl group is closer to
Tyr308 at H7 but not forming any hydrogen bond interaction.
Figure S9B shows this pose from a top view from the cytoplasmic
site of b2AR. The catechol ring of epinephrine is located between
Phe193 at the EC loop 2 and Phe289 at H6 forming p-stacking
interactions with both of these residues. Asp113 at H3 and Asn312
at H6 are at the closer vicinity of the b-hydroxyl and amine groups
of epinephrine. The epinephrine molecules in complex with the
active BI-167107 bound structure are shown in pink color.
(TIF)
Figure S10 Binding of modes salmeterol, R, R formo-
terol and epinephrine to b2AR. ANM-restrained MD
conformations that accommodate b2AR agonists with experimen-
tally verified interactions are shown. The ANM-restrained MD
conformations-ligands complexes are with salmeterol, R, R
formoterol and epinephrine are shown in the left-, center- and
right panels, respectively. The side chains of the residues that are
3.5 A˚
´
of the ligands are displayed. Coloring of the atoms are the
same as in Figure 4. The EC2 that interacts with salmeterol is
shown in green in the first panel. All b-hydroxyl and protonated
amine groups of the ligands are forming hydrogen bonds with
Asp113 at H3. The hydroxyl groups of the aromatic rings of all
ligands are forming hydrogen bonds with Serines at H5.
Epinephrine binds to the orthosteric binding site slightly closer
to the EC site compared to the larger ligands, salmeterol and R, R
formoterol.
(TIF)
Figure S11 The Comparison of the millisecond scale
MD simulation snapshots with the inactive crystal
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structure of b2AR. The left panels show the ribbon diagrams of
the apo (A) and carazolol (B) bound snapshots that are
superimposed to the inactive carazolol bound crystal structure.
The most pronounced conformational changes are denoted by the
arrows. The right panels show the corresponding binding sites of
these snapshots compared to the crystal structure. The carbon
atoms of the MD snapshots and the crystal structure side chains
are colored cyan and green, respectively. The rest of the atoms and
the helices are colored in accord with the rest of the document.
(TIF)
Figure S12 Alprenolol in ANM restrained MD confor-
mation and in the crystal structure complex. Binding
residues of alprenolol in ANM-restrained-MD conformation (A)
and in the crystal structure (B). Carbon atoms of alprenolol in
ANM-restrained-MD conformation (6P) and the crystal structures
colored green and pink, respectively. The heavy atoms of the
residues that are in the 4.5 A of alprenolol are displayed and
labeled. Both structures have the same residues in the vicinity of
alprenolol and display similar orientations. Unlike agonists of
b2AR alprenolol does not contain hydroxyl groups that interact
with the Serine residues at H5. In both structures Ser203 and
Ser207 are not rotated towards the binding cavity of b2AR.
Instead, the head group of alprenolol is stabilized at the binding
site with the p-stacking interaction with the so-called rotamer
toggle switch, Phe290 at H6. The rest of the atoms are colored in
the same pattern as in the rest of the manuscript.
(TIF)
Figure S13 Refining drug target network by assessing
protein motion. In current drug target network representations
drug targets (gray circles) are interpreted as single entities
connected through drugs (black circles), and the particular
biologically relevant protein conformations that a drug preferen-
tially binds are ignored. However, to fully understand the
interactions of drugs to their targets a target should be represented
by its different functionally relevant conformations (different
colored shapes within grey line enclosed areas). Drug targets that
are represented by single structures are connected to drugs by blue
dashed lines. The target conformations that preferentially bind a
drug are connected by red dashed lines.
(TIF)
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